SUPN +23%Here we see a strong impulse and long correction during almost 2 years. Now it’s breakout and going higher.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.02EUR
1.19 MEUR
550.42 MEUR
52.62 M
About Supernus Pharmaceuticals, Inc.
Sector
CEO
Jack A. Khattar
Headquarters
Rockville
Website
Employees (FY)
652
Founded
2005
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
SUPN going upWhat used to be a resistance now a support.
Plus an inverse head & shoulders.
Plus positive news: “Supernus said that a Phase 3 trial 'met the primary endpoint ... compared to placebo in improving the symptoms of ADHD.'"
Going long anticipating 30’s where MA200 is and then maybe higher.
With tight s
$SUPN Supernus Pharmaceuticals Bull flag This share reports earnings today. Downtrend broken and building what looks like a bull flag. Targets 29.40 and 33 if this bull flag breaks to the upside.
SUPN LongMonthly trend change on wave trend indicator. 4 hour chart looks strong. VIX oversold signal screaming oversold. What's not to like?
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of S49 is 28.40 EUR — it hasn't changed in the past 24 hours. Watch SUPERNUS PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange SUPERNUS PHARMACEUTICALS INC stocks are traded under the ticker S49.
SUPERNUS PHARMACEUTICALS INC is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
S49 stock is 0% volatile and has beta coefficient of 0.93. Track SUPERNUS PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is SUPERNUS PHARMACEUTICALS INC there?
S49 earnings for the last quarter are 0.80 EUR per share, whereas the estimation was 0.50 EUR resulting in a 59.50% surprise. The estimated earnings for the next quarter are 0.24 EUR per share. See more details about SUPERNUS PHARMACEUTICALS INC earnings.
SUPERNUS PHARMACEUTICALS INC revenue for the last quarter amounts to 148.87 M EUR despite the estimated figure of 140.46 M EUR. In the next quarter revenue is expected to reach 135.15 M EUR.
Yes, you can track SUPERNUS PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
S49 stock has fallen by 1.39% compared to the previous week, the month change is a 7.79% fall, over the last year SUPERNUS PHARMACEUTICALS INC has showed a 14.97% decrease.
S49 net income for the last quarter is 1.06 M EUR, while the quarter before that showed −15.11 M EUR of net income which accounts for 107.04% change. Track more SUPERNUS PHARMACEUTICALS INC financial stats to get the full picture.
Today SUPERNUS PHARMACEUTICALS INC has the market capitalization of 1.55 B, it has increased by 0.81% over the last week.
No, S49 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, S49 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SUPERNUS PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
As of May 7, 2024, the company has 652.00 employees. See our rating of the largest employees — is SUPERNUS PHARMACEUTICALS INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SUPERNUS PHARMACEUTICALS INC technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SUPERNUS PHARMACEUTICALS INC stock shows the neutral signal. See more of SUPERNUS PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on SUPERNUS PHARMACEUTICALS INC future price: according to them, S49 price has a max estimate of 39.68 EUR and a min estimate of 35.06 EUR. Watch S49 chart and read a more detailed SUPERNUS PHARMACEUTICALS INC stock forecast: see what analysts think of SUPERNUS PHARMACEUTICALS INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SUPERNUS PHARMACEUTICALS INC EBITDA is 89.01 M EUR, and current EBITDA margin is 16.17%. See more stats in SUPERNUS PHARMACEUTICALS INC financial statements.